 |
|  |
Dec-06-19 | Reiterated |
RBC Capital Mkts |
Outperform |
$190 → $100 |
|
Dec-05-19 | Reiterated |
Guggenheim |
Buy |
$200 → $110 |
|
Dec-05-19 | Downgrade |
SunTrust |
Buy → Hold |
|
|
Oct-30-19 | Initiated |
H.C. Wainwright |
Neutral |
$160 |
|
May-23-19 | Initiated |
Wedbush |
Outperform |
|
|
Apr-25-19 | Initiated |
Jefferies |
Buy |
$195 |
|
Dec-14-18 | Initiated |
Wolfe Research |
Outperform |
|
|
Oct-11-18 | Initiated |
Oppenheimer |
Outperform |
$170 |
|
Aug-07-18 | Reiterated |
Stifel |
Buy |
$198 → $239 |
|
Aug-06-18 | Initiated |
Piper Jaffray |
Overweight |
$206 |
|
Jun-06-18 | Initiated |
Ladenburg Thalmann |
Buy |
$230 |
|
Mar-26-18 | Resumed |
Canaccord Genuity |
Buy |
$210 |
|
Feb-26-18 | Initiated |
Morgan Stanley |
Overweight |
|
|
Dec-08-17 | Reiterated |
Needham |
Buy |
$100 → $193 |
|
Dec-08-17 | Reiterated |
Canaccord Genuity |
Buy |
$140 → $191 |
|
Dec-07-17 | Reiterated |
Chardan Capital Markets |
Buy |
$140 → $225 |
|
Nov-10-17 | Upgrade |
Chardan Capital Markets |
Neutral → Buy |
$60 → $140 |
|
Nov-10-17 | Reiterated |
Needham |
Buy |
$86 → $100 |
|
Oct-06-17 | Resumed |
Goldman |
Buy |
$87 |
|
Sep-15-17 | Initiated |
RBC Capital Mkts |
Outperform |
$117 |
|
|
 |
Dec-14-19 02:56PM | Notable Insider Buys In The Past Week: Enterprise Products Partners, PBF Energy, Sage Therapeutics Benzinga |
Dec-12-19 08:15PM | HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. (SAGE) Investors With 100K+ Losses to Contact Its Attorneys, Securities Fraud Investigation Opened ACCESSWIRE +5.71% |
10:38AM | Trade Alert: The Chief Scientific Officer Of Sage Therapeutics, Inc. (NASDAQ:SAGE), Albert Robichaud, Has Just Spent US$1.6m Buying Shares Simply Wall St. |
Dec-11-19 08:01PM | HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. (SAGE) Investors With 100K+ Losses to Contact Its Attorneys, Securities Fraud Investigation Opened GlobeNewswire +8.50% |
09:41AM | Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar Zacks |
Dec-10-19 09:18PM | HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. (SAGE) Investors With 100K+ Losses to Contact Its Attorneys, Securities Fraud Investigation Opened PR Newswire |
07:30AM | Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington's Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP) Business Wire |
Dec-09-19 10:20AM | Sage Therapeutics (SAGE) in Focus: Stock Moves 7.1% Higher Zacks |
06:20AM | SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Is Investigating the Officers and Directors of Sage Therapeutics, Inc. (SAGE) on Behalf of Shareholders ACCESSWIRE |
Dec-06-19 03:00PM | Sell-Side Remains Optimistic On Sage Therapeutics Despite Depression Drug Disappointment Benzinga +7.11% |
09:30AM | Sage Therapeutics Stock Collapsed After Depression-Drug Results. Analysts Say It Has Lost Enough Ground. Barrons.com |
09:26AM | Sage Therapeutics' Depression Drug Fails in Study, Stock Down Zacks |
Dec-05-19 08:31PM | Lost Money in Sage Therapeutics, Inc.? Business Wire -59.67% |
04:18PM | 6 Underperforming Stocks in Gurus' Portfolios GuruFocus.com |
04:05PM | This Biotech Collapsed 60% After Its Depression Drug Unexpectedly Failed Investor's Business Daily |
11:00AM | Sage Shareholders Face Classic Biotech Investor Dilemma Bloomberg |
10:24AM | Sage Therapeutics Stock Is Cratering Because Its Depression Treatment Failed in a Key Trial Barrons.com |
09:54AM | Shares of Cambridge biotech plunge as depression drug fails late-stage trial American City Business Journals |
09:42AM | Sage Plunges as Key Depression Study Fails to Show Benefit Bloomberg |
07:21AM | UPDATE 1-Sage's oral depression therapy fails in late-stage trial; shares plunge Reuters |
07:18AM | Sage Therapeutics's stock plunges after depression treatment study fails primary endpoint MarketWatch |
06:40AM | Sage's oral depression therapy fails in late-stage trial Reuters |
06:30AM | Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder Business Wire |
Dec-04-19 09:28AM | Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy ? Insider Monkey |
Dec-03-19 04:30PM | Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire |
09:57AM | Edited Transcript of SAGE earnings conference call or presentation 12-Nov-19 1:00pm GMT Thomson Reuters StreetEvents |
Nov-25-19 06:44PM | Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Sage Therapeutics, Inc. (SAGE) on Behalf of Shareholders Business Wire |
Nov-20-19 06:10PM | These 3 Strong Buy Healthcare Stocks Have 40% Upside Or More, Says Cowen TipRanks |
Nov-15-19 10:02AM | VistaGen's (VTGN) Major Depressive Disorder Drug Disappoints Zacks |
Nov-12-19 06:31AM | Sage Therapeutics Announces Third Quarter 2019 Financial Results and Highlights Pipeline and Business Progress Business Wire |
Nov-11-19 04:30PM | Sage Therapeutics to Present at the Stifel 2019 Healthcare Conference Business Wire |
07:50AM | 5 Biotech Stocks Set to Beat Q3 Earnings Estimates Zacks |
Nov-05-19 06:00PM | Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire |
12:01PM | Is Sage Therapeutics, Inc.'s (NASDAQ:SAGE) CEO Salary Justified? Simply Wall St. |
Oct-30-19 01:49PM | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Sage Therapeutics, Inc.- SAGE GlobeNewswire |
Oct-23-19 02:29PM | Drugmaker Alkermes cuts 160 jobs in effort to lower expenses American City Business Journals |
Oct-20-19 06:06PM | Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy? Insider Monkey |
Oct-14-19 03:42AM | Moving Average Crossover Alert: Sage Therapeutics Zacks |
Oct-09-19 06:18PM | This Hedge Fund Returns 22% Annually, Here Are Its Latest Picks Insider Monkey |
06:30AM | Sage Therapeutics to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019 Business Wire |
Oct-03-19 10:52AM | Sage Therapeutics Is Pointed Down So We Are In No Rush to Buy TheStreet.com |
Oct-02-19 04:30PM | Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire |
06:30AM | Sage Therapeutics to Participate in J.P. Morgan Executive Conference Call Series Business Wire |
Sep-20-19 02:04PM | Here's Why We're Watching Sage Therapeutics's (NASDAQ:SAGE) Cash Burn Situation Simply Wall St. |
01:10PM | Gilead, AbbVie Are Innovative, but May Be Underappreciated GuruFocus.com |
Sep-05-19 04:31PM | Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire |
Sep-04-19 05:05PM | Sage Therapeutics Announces the New England Journal of Medicine Publishes Data from Phase 2 Trial with SAGE-217 in Major Depressive Disorder Business Wire |
Sep-03-19 05:31PM | Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference Business Wire -6.34% |
Aug-14-19 12:35PM | Edited Transcript of SAGE earnings conference call or presentation 6-Aug-19 12:00pm GMT Thomson Reuters StreetEvents |
Aug-06-19 06:30AM | Sage Therapeutics Announces Second Quarter 2019 Financial Results and Highlights Pipeline and Business Progress Business Wire |
Aug-05-19 04:30PM | Sage Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference Business Wire |
06:30AM | Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire |
Jul-30-19 10:38AM | Earnings Preview: Sage Therapeutics (SAGE) Q2 Earnings Expected to Decline Zacks |
Jul-24-19 06:30AM | Sage Therapeutics Announces Clinical Updates and Progress Across Neuroscience Pipeline During Sage FutureCast Business Wire |
Jul-23-19 01:53PM | Here's Why Marinus Pharmaceuticals Stock Is Collapsing Today Motley Fool |
Jul-11-19 06:30AM | Sage Therapeutics to Report Second Quarter 2019 Financial Results on Tuesday, August 6, 2019 Business Wire |
Jul-10-19 01:14PM | Spiros Segalas' Top 5 Buys of the 2nd Quarter GuruFocus.com |
Jul-09-19 06:40AM | Is Sage Therapeutics's (NASDAQ:SAGE) 287% Share Price Increase Well Justified? Simply Wall St. |
Jul-03-19 06:30AM | Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire |
Jun-27-19 12:46PM | 5 stocks trading at under $10 worth discovering MarketWatch +5.37% |
06:30AM | Sage Therapeutics to Host Sage FutureCast Webcast Business Wire |
Jun-19-19 08:12PM | Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy? Insider Monkey |
Jun-18-19 06:30AM | Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference Business Wire |
Jun-14-19 02:07PM | Why Sage Therapeutics' new Brier Creek center came at the perfect time American City Business Journals |
08:53AM | Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling of ZULRESSO (brexanolone) Injection Business Wire |
Jun-06-19 09:17AM | Life sciences VC firm Third Rock raises $770M in its largest round ever American City Business Journals |
Jun-05-19 06:30AM | Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire |
Jun-04-19 06:30AM | Sage Therapeutics to Present at Goldman Sachs 40th Annual Global Healthcare Conference Business Wire |
May-29-19 07:15PM | Sage Therapeutics Inc (SAGE) President & CEO Jeffrey M Jonas Sold $15 million of Shares GuruFocus.com |
May-24-19 08:15PM | Sage Therapeutics Inc (SAGE) President & CEO Jeffrey M Jonas Sold $16.5 million of Shares GuruFocus.com |
May-23-19 09:06AM | Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE PR Newswire |
May-22-19 07:02AM | Are Investors Undervaluing Sage Therapeutics, Inc. (NASDAQ:SAGE) By 29%? Simply Wall St. |
May-20-19 09:04AM | Ligand Grants Preclinical Candidate Rights to UK-based Firm Zacks |
May-14-19 06:30AM | Sage Therapeutics to Present at 2019 RBC Capital Markets Global Healthcare Conference Business Wire |
May-13-19 04:08PM | Edited Transcript of SAGE earnings conference call or presentation 2-May-19 12:00pm GMT Thomson Reuters StreetEvents |
May-09-19 07:07AM | New England Venture Capital Association names 2019 NEVY Awards winners American City Business Journals |
May-08-19 09:27AM | Small-Cap Stocks to Watch in May Motley Fool |
May-07-19 04:01PM | Sage Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference Business Wire |
May-06-19 04:45PM | Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire |
May-02-19 06:30AM | Sage Therapeutics Announces First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress Business Wire |
06:00AM | SAGE Therapeutics, Inc. to Host Earnings Call ACCESSWIRE |
05:20AM | These 6 biotech stocks are promising takeover targets MarketWatch |
Apr-29-19 10:47AM | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Sage Therapeutics, Inc. GlobeNewswire |
Apr-27-19 09:30AM | Sage Therapeutics' Zulresso is a big win for postpartum depression sufferers and maybe even the entire mental health community CNBC |
09:16AM | How a failed epilepsy drug became a $34,000 postpartum cure CNBC Videos |
Apr-26-19 06:10AM | Analysts point to potential Biogen M&A options after Alzheimer's failure American City Business Journals |
Apr-24-19 10:45AM | Did Hedge Funds Drop The Ball On SAGE Therapeutics Inc (SAGE) ? Insider Monkey |
Apr-18-19 04:30PM | Sage Therapeutics to Report First Quarter 2019 Financial Results on Thursday, May 2, 2019 Business Wire |
Apr-03-19 06:30AM | Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire |
Apr-01-19 09:25AM | The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage Zacks |
Mar-25-19 08:49AM | 5 biotech stocks that could be the next big winners MarketWatch |
Mar-23-19 10:02AM | 2 Biotech Takeout Targets Perfect for Biogen Motley Fool |
Mar-21-19 09:59AM | A Big Outside Day and Lower Close on Sage Therapeutics Looks Bearish to Me TheStreet.com |
06:53AM | Shares of Sage Therapeutics up on Zulresso approval, but analysts expect a slow rollout MarketWatch |
Mar-20-19 10:16PM | Is Sage Therapeutics a Good Stock to Buy Now? Motley Fool |
08:35PM | Fed Stops the Rate Madness: Cramer's 'Mad Money' Recap (Wednesday 3/20/19) TheStreet.com |
07:08PM | Sage Therapeutics CEO: Getting the first postpartum depre... CNBC Videos |
04:18PM | This Biotech Stock Grabbed A First In Depression So What's Next? Investor's Business Daily |
12:44PM | The Late Morning Rundown: March 20, 2019 CNBC Videos |
11:21AM | Sage's First-Of-Its-Kind Postpartum Depression Drug Clears FDA Hurdle: What You Need to Know Benzinga |
|
|
|
 |
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain; and SAGE-689, a novel GABAA receptor positive allosteric modulator that is in preclinical stage to treat acute and chronic CNS disorders. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. |
 |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
IGUCHI KIMI | CFO & Treasurer | Dec 10 | Option Exercise | 1.36 | 500 | 680 | 29,261 | Dec 10 09:26 PM | Robichaud Albert | Chief Scientific Officer | Dec 09 | Option Exercise | 20.12 | 15,743 | 316,746 | 111,400 | Dec 10 08:04 PM | IGUCHI KIMI | CFO & Treasurer | Dec 09 | Option Exercise | 1.36 | 15,000 | 20,400 | 28,761 | Dec 10 09:26 PM | JONAS JEFFREY M | President & CEO | Dec 09 | Buy | 64.20 | 7,500 | 481,500 | 54,530 | Dec 10 08:04 PM | Robichaud Albert | Chief Scientific Officer | Dec 09 | Buy | 64.16 | 25,000 | 1,604,000 | 136,400 | Dec 10 08:04 PM | JONAS JEFFREY M | President & CEO | Sep 11 | Option Exercise | 0.45 | 4,600 | 2,070 | 47,030 | Sep 12 05:00 PM | Kanes Stephen | Chief Medical Officer | Sep 04 | Option Exercise | 0.45 | 6,000 | 2,700 | 8,292 | Sep 05 04:33 PM | FRATES JAMES M | Director | Aug 15 | Option Exercise | 28.35 | 8,000 | 226,800 | 10,535 | Aug 16 04:04 PM | FRATES JAMES M | Director | Aug 15 | Sale | 160.58 | 8,000 | 1,284,640 | 2,535 | Aug 16 04:04 PM | IGUCHI KIMI | CFO & Treasurer | Jul 25 | Option Exercise | 1.36 | 2,000 | 2,720 | 12,409 | Jul 25 06:02 PM | IGUCHI KIMI | CFO & Treasurer | Jul 17 | Option Exercise | 1.36 | 4,000 | 5,440 | 10,409 | Jul 17 04:02 PM | JONAS JEFFREY M | President & CEO | Jul 16 | Option Exercise | 0.45 | 27,000 | 12,150 | 39,115 | Jul 17 04:01 PM | JONAS JEFFREY M | President & CEO | May 29 | Sale | 170.61 | 1,075 | 183,401 | 12,115 | May 29 04:01 PM | JONAS JEFFREY M | President & CEO | May 28 | Option Exercise | 0.45 | 35,736 | 16,081 | 97,851 | May 29 04:01 PM | JONAS JEFFREY M | President & CEO | May 28 | Sale | 174.83 | 84,661 | 14,801,189 | 13,190 | May 29 04:01 PM | JONAS JEFFREY M | President & CEO | May 24 | Option Exercise | 0.45 | 40,356 | 18,160 | 102,471 | May 24 06:24 PM | JONAS JEFFREY M | President & CEO | May 24 | Sale | 175.08 | 40,356 | 7,065,543 | 62,115 | May 24 06:24 PM | JONAS JEFFREY M | President & CEO | May 23 | Option Exercise | 0.45 | 53,908 | 24,259 | 116,023 | May 24 06:24 PM | JONAS JEFFREY M | President & CEO | May 23 | Sale | 174.51 | 53,908 | 9,407,253 | 62,115 | May 24 06:24 PM | Cloonan Michael | Chief Business Officer | May 22 | Option Exercise | 73.43 | 25,000 | 1,835,750 | 25,461 | May 24 04:00 PM | Cloonan Michael | Chief Business Officer | May 22 | Sale | 175.00 | 25,000 | 4,375,000 | 461 | May 24 04:00 PM | Cook Anne Marie | SVP, GC & Secretary | May 10 | Option Exercise | 29.86 | 15,700 | 468,839 | 15,000 | May 10 04:31 PM | Cook Anne Marie | SVP, GC & Secretary | May 10 | Sale | 166.14 | 15,000 | 2,492,100 | 0 | May 10 04:31 PM | FRATES JAMES M | Director | May 06 | Option Exercise | 8.92 | 8,000 | 71,360 | 12,235 | May 06 06:21 PM | FRATES JAMES M | Director | May 06 | Sale | 162.22 | 8,000 | 1,297,760 | 4,235 | May 06 06:21 PM | PAUL STEVEN M | Director | Mar 21 | Sale | 161.04 | 7,879 | 1,268,824 | 122,400 | Mar 22 04:22 PM | PAUL STEVEN M | Director | Mar 20 | Sale | 161.29 | 56,646 | 9,136,582 | 130,279 | Mar 20 08:47 PM | PAUL STEVEN M | Director | Mar 18 | Sale | 161.05 | 3,775 | 607,977 | 186,925 | Mar 20 08:47 PM | IGUCHI KIMI | CFO & Treasurer | Mar 08 | Option Exercise | 0.45 | 4,723 | 2,125 | 6,136 | Mar 11 05:03 PM | IGUCHI KIMI | CFO & Treasurer | Mar 01 | Sale | 156.93 | 25,563 | 4,011,602 | 1,413 | Mar 01 04:46 PM | PAUL STEVEN M | Director | Feb 25 | Sale | 161.00 | 2,000 | 322,000 | 70,900 | Feb 27 05:48 PM | PAUL STEVEN M | Director | Feb 19 | Sale | 161.62 | 1,543 | 249,373 | 72,900 | Feb 20 07:55 AM | PAUL STEVEN M | Director | Feb 15 | Sale | 161.02 | 49,461 | 7,964,210 | 74,443 | Feb 20 07:55 AM | Kanes Stephen | Chief Medical Officer | Feb 08 | Sale | 150.00 | 22,948 | 3,442,200 | 941 | Feb 08 05:08 PM | FRATES JAMES M | Director | Jan 23 | Option Exercise | 8.92 | 7,500 | 66,900 | 11,735 | Jan 24 05:44 PM | FRATES JAMES M | Director | Jan 23 | Sale | 134.81 | 7,500 | 1,011,075 | 4,235 | Jan 24 05:44 PM | JONAS JEFFREY M | President & CEO | Jan 09 | Option Exercise | 0.45 | 10,000 | 4,500 | 62,115 | Jan 10 05:16 PM |
|
 |
|
 |
|